What are the contraindications for Talazoparib/Tazena?

Talazoparib As aPARP inhibitor, it has received great attention in recent years in the treatment ofbreast cancer and prostate cancer. Its mechanism of action is mainly by inhibiting the DNA repair pathway, thereby selectively killing cancer cells with BRCA mutations. However, while any targeted drug brings benefits, it also has specific contraindications, which are crucial to clinical safety. According to the medication information and guideline interpretation, the contraindications of talazoparib mainly involve the following aspects.

First, the clearest contraindication is in patients with a severe allergic reaction to talazoparib or any component of the formulation. Allergic reactions may manifest as severe rash, difficulty breathing, facial or throat edema, etc. Once this occurs, the drug must be stopped immediately and the use of such drugs should be avoided in the future. Secondly, severe myelosuppression is a high-risk group during medication, especially patients with obvious anemia, thrombocytopenia or neutropenia at baseline. If bone marrow function is at a low level before treatment, the drug may further aggravate bone marrow suppression and cause serious complications.

In addition, pregnant and lactating women are also clearly contraindicated. BecausePARP inhibitors may cause teratogenic risks to fetal development, pregnancy screening is required before treatment and reliable contraceptive measures are taken during treatment. Likewise, breastfeeding women need to avoid taking the drug to avoid potential toxicity to the baby through the milk. In addition, patients with severe hepatic and renal impairment should be carefully evaluated before use. Although not absolutely contraindicated, since the drug is primarily excreted through the kidneys, patients with renal insufficiency may experience accumulation of the drug, thereby increasing the risk of toxicity.

Reference materials:https://www.talzenna.com/